Is AIM or AKTS more undervalued in 2026?

CirclFi compares AIM ImmunoTech Inc. (AIM) and Aktis Oncology, Inc. (AKTS) using 13 institutional-grade valuation models. AIM has a Quality of Company score of 4.2/10 while AKTS scores 1.6/10.

Which is a better buy — AIM or AKTS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do AIM and AKTS valuations compare?

AIM at $0.44 and AKTS at $20.43 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

AIM vs AKTS Valuation Comparison 2026 — Intrinsic Value Analysis

AIM

Biotechnology

AIM ImmunoTech Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$0.44

Last close

Models

8/13

Active

AKTS

Biotechnology

Aktis Oncology, Inc.

Quality

1.6

out of 10

Value Trap

—

Price

$20.43

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	AIM Fair Value	AIM Upside	AKTS Fair Value	AKTS Upside
Bayesian DCF	Intrinsic	$0.14	-66.9%	$5.41	-73.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.51	+245.6%	$4.70	-77.0%
PWERM	Option-Based	$0.65	+48.4%	$9.59	-53.0%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for AIM vs AKTS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

AIM vs AKTS — Which Stock Is More Undervalued?

AIM scores higher with a 4.2/10 quality rating vs AKTS's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing AIM ImmunoTech Inc. (AIM) and Aktis Oncology, Inc. (AKTS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

AIM currently trades at $0.44 with a QOC of 4.2/10, while AKTS trades at $20.43 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).